Intech Investment Management LLC Acquires Shares of 57,774 Hims & Hers Health, Inc. (NYSE:HIMS)

Intech Investment Management LLC bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 57,774 shares of the company's stock, valued at approximately $1,064,000.

A number of other institutional investors have also added to or reduced their stakes in HIMS. Quest Partners LLC boosted its holdings in Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company's stock valued at $81,000 after purchasing an additional 807 shares in the last quarter. Royce & Associates LP lifted its position in shares of Hims & Hers Health by 17.0% during the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company's stock worth $6,281,000 after buying an additional 49,500 shares during the period. Victory Capital Management Inc. boosted its stake in Hims & Hers Health by 164.9% in the 3rd quarter. Victory Capital Management Inc. now owns 51,577 shares of the company's stock valued at $950,000 after buying an additional 32,108 shares in the last quarter. WealthPlan Investment Management LLC bought a new stake in Hims & Hers Health in the third quarter valued at $1,042,000. Finally, Versor Investments LP acquired a new position in Hims & Hers Health during the third quarter worth $634,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on HIMS. Bank of America lowered shares of Hims & Hers Health from a "buy" rating to an "underperform" rating and lowered their target price for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Needham & Company LLC started coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They set a "buy" rating and a $24.00 price objective on the stock. Canaccord Genuity Group lifted their target price on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. TD Cowen reissued a "buy" rating and issued a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $20.71.

Hims & Hers Health Trading Down 1.1 %

Shares of HIMS traded down $0.34 on Thursday, reaching $30.34. 24,738,795 shares of the company's stock were exchanged, compared to its average volume of 9,806,751. The business has a 50 day moving average price of $21.42 and a two-hundred day moving average price of $19.65. Hims & Hers Health, Inc. has a 12 month low of $8.09 and a 12 month high of $35.02. The stock has a market capitalization of $6.63 billion, a P/E ratio of 68.95 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $401.56 million during the quarter, compared to analysts' expectations of $382.20 million. During the same quarter in the previous year, the company posted ($0.04) EPS. The business's revenue for the quarter was up 77.1% compared to the same quarter last year. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insiders Place Their Bets

In related news, insider Soleil Boughton sold 2,343 shares of the company's stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $29.90, for a total value of $70,055.70. Following the completion of the transaction, the insider now directly owns 165,254 shares of the company's stock, valued at approximately $4,941,094.60. This represents a 1.40 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the sale, the chief executive officer now owns 33,502 shares in the company, valued at $487,789.12. The trade was a 84.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,153,519 shares of company stock worth $24,486,721. Insiders own 17.71% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.